Results of a systematic review and meta-analysis were consistent across age groups, diabetes types, and regions of the world. The study authors suggested that earlier vaccination against herpes zoster in all patients with diabetes, regardless of age,
British patients with type 1 diabetes were enrolled in group training courses that taught flexible intensive insulin treatment and then randomized to an insulin pump or multiple daily injections and followed for two years.
The trial of semaglutide included 3,297 patients with type 2 diabetes, 83% of whom had established cardiovascular disease, chronic kidney disease, or both.
An observational study based on U.S. data compared hazard ratios for death based on overall, unhealthy, and healthy low-carb diet scores according to percentage of energy obtained from total and subtypes of carbohydrate, protein, and fat.
In a cross-sectional survey at an Ohio health system, 67% of respondents with non-insulin-controlled type 2 diabetes said they monitored their blood glucose levels because their physician had asked them to, and 50% said they would stop if given
In a systematic review and meta-analysis of eight randomized controlled trials, glucagon-like peptide-1 (GLP-1) receptor agonists reduced major adverse cardiovascular events by 14%, all-cause mortality by 12%, hospital admission for heart failure by
The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial, which was funded by Novo Nordisk and the National Institutes of Health, randomized 9,340 patients ages 50 years and older to 1.8 mg of
population. “Taken together, these findings highlight the importance of age at onset of diabetes and cardiovascular comorbidity in persons with diabetes for risk of dementia,” the authors wrote.
In patients with diabetes and depression in Taiwan, regular use of an antidepressant was associated with a 0.92-fold decreased risk of macrovascular complications and a 0.86-fold decreased risk of all-cause mortality compared with poor adherence.
A systematic review and meta-analysis found that proton-pump inhibitors (PPIs) improved glycemic indices in patients with diabetes and did not appear to affect risk for incident diabetes.